Archemix and Lilly in Aptamer deal
This article was originally published in Scrip
Archemix and Lilly are to explore the development of new aptamer-based drugs. The US biotechnology company will license certain IP rights from Lilly, which in return has an option to evaluate aptamers for certain drug targets. Lilly retains an option to enter into an exclusive licence with Archemix for up to two of the aptamer targets. No financial details were disclosed. Aptamers are synthetically derived oligonucleotides (short nucleic acid sequences) that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action.